Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Ulcerative Colitis HELP
Based on 9,896 articles published since 2007
||||

These are the 9896 published articles about Colitis, Ulcerative that originated from Worldwide during 2007-2017.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline [Second Korean Guideline for the Management of Ulcerative Colitis]. 2017

Choi, Chang Hwan / Moon, Won / Kim, You Sun / Kim, Eun Soo / Lee, Bo In / Jung, Yunho / Yoon, Yong Sik / Lee, Heeyoung / Park, Dong Il / Han, Dong Soo / Anonymous17141247. ·Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea. · Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. · Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea. · Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea. · Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. · Division of Gastroenterology, Department of Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea. · Division of Colon and Rectal Surgery, Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea. · Center for Preventive Medicine and Public Health, Seoul National University Bundang Hospital, Seongnam, Korea. · Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. · Department of Internal Medicine, Hanyang University College of Medicine, Guri, Korea. · ·Korean J Gastroenterol · Pubmed #28135789.

ABSTRACT: Ulcerative colitis (UC) is a chronic inflammatory bowel disorder characterized by a relapsing and remitting course. The direct and indirect costs of the treatment of UC are high, and the quality of life of patients is reduced, especially during exacerbation of the disease. The incidence and prevalence of UC in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Various medical and surgical therapies, including biologics, are currently used for the management of UC. However, many challenging issues exist, which sometimes lead to differences in practice between clinicians. Therefore, the Inflammatory Bowel Disease Study Group of the Korean Association for the Study of Intestinal Diseases established the first Korean guideline for the management of UC in 2012. This is an update of the first guideline. It was generally made by the adaptation of several foreign guidelines as was the first edition, and encompasses treatment of active colitis, maintenance of remission, and indication of surgery for UC. The specific recommendations are presented with the quality of evidence and classification of recommendations.

2 Guideline Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. 2017

Yamamoto-Furusho, J K / Bosques-Padilla, F / de-Paula, J / Galiano, M T / Ibañez, P / Juliao, F / Kotze, P G / Rocha, J L / Steinwurz, F / Veitia, G / Zaltman, C. ·Clínica de Enfermedad Inflamatoria Intestinal, Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México. Electronic address: kazuofurusho@hotmail.com. · Gastroenterology Division, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México; Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey, Monterrey, México. · Servicio de Gastroenterología, Hospital Italiano, Buenos Aires, Argentina. · Clínica de Enfermedad Inflamatoria Intestinal, Clínica Marly, Bogotá, Colombia. · Programa de Enfermedad Inflamatoria Intestinal, Departamento de Gastroenterología, Clínica Las Condes, Santiago, Chile. · Clínica de Enfermedad Inflamatoria Intestinal, Hospital Pablo Tobón Uribe, Medellín, Colombia. · Hospital Universitario Cajuru, Universidad Católica del Paraná (PUCPR), Curitiba, Brasil. · Grupo Académico y de Investigación sobre Enfermedad de Crohn y Colitis Ulcerosa Crónica Idiopática de México, Ciudad de México, México. · Hospital Israelita Albert Einstein, São Paulo, Brasil. · Servicio de Gastroenterología, Hospital Vargas, Caracas, Venezuela. · Servicio de Gastroenterología, Hospital Clementino Fraga Filho, Departamento de Medicina Interna, Universidade Federal do Rio de Janeiro (UFRJ), Río de Janeiro, Brasil. ·Rev Gastroenterol Mex · Pubmed #27979414.

ABSTRACT: The incidence and prevalence of inflammatory bowel disease (IBD) has increased in recent years in several Latin American countries. There is a need to raise awareness in gastroenterologists and the population in general, so that early diagnosis and treatment of ulcerative colitis (UC) and Crohn's Disease (CD) can be carried out. It is important for all physicians to have homogeneous criteria regarding the diagnosis and treatment of IBD in Latin America. The Pan American Crohn's and Colitis Organisation (PANCCO) is an organization that aims to include all the countries of the Americas, but it specifically concentrates on Latin America. The present Consensus was divided into two parts for publication: 1) Diagnosis and treatment and 2) Special situations. This is the first Latin American Consensus whose purpose is to promote a perspective adapted to our Latin American countries for the diagnosis, treatment, and monitoring of patients with UC and CD.

3 Guideline French national consensus clinical guidelines for the management of ulcerative colitis. 2016

Peyrin-Biroulet, Laurent / Bouhnik, Yoram / Roblin, Xavier / Bonnaud, Guillaume / Hagège, Hervé / Hébuterne, Xavier / Anonymous2411244. ·Service d Hépato-Gastroentérologie, CHU de Nancy, Vandœuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com. · Service de Gastro-entérologie, MICI et Assistance Nutritive, CHU Paris Nord-Val de Seine, APHP, DHU UNITY, Hôpital Beaujon, Clichy, France. · Service de Gastro-entérologie et Hépatologie, CHU St Etienne, St Etienne, France. · Clinique Ambroise Paré, Toulouse, France. · Service d hépato-gastroentérologie, CHI Créteil, France. · Service de Gastro-entérologie et nutrition, Hôpital de l'Archet, CHU de Nice, France. · ·Dig Liver Dis · Pubmed #27158125.

ABSTRACT: BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory bowel disease of multifactorial etiology that primarily affects the colonic mucosa. The disease progresses over time, and clinical management guidelines should reflect its dynamic nature. There is limited evidence supporting UC management in specific clinical situations, thus precluding an evidence-based approach. AIM: To use a formal consensus method - the nominal group technique (NGT) - to develop a clinical practice expert opinion to outline simple algorithms and practices, optimize UC management, and assist clinicians in making treatment decisions. METHODS: The consensus was developed by an expert panel of 37 gastroenterologists from various professional organizations with experience in UC management using the qualitative and iterative NGT, incorporating deliberations based on the European Crohn's and Colitis Organisation recommendations, recent reviews of scientific literature, and pertinent discussion topics developed by a steering committee. Examples of clinical cases for which there are limited evidence-based data from clinical trials were used. Two working groups proposed and voted on treatment algorithms that were then discussed and voted for by the nominal group as a whole, in order to reach a consensus. RESULTS: A clinical practice guideline covering management of the following clinical situations was developed: (i) moderate and severe UC; (ii) acute severe UC; (iii) pouchitis; (iv) refractory proctitis, in the form of treatment algorithms. CONCLUSIONS: Given the limited available evidence-based data, a formal consensus methodology was used to develop simple treatment guidelines for UC management in different clinical situations that is now accessible via an online application.

4 Guideline The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. 2016

Nguyen, Geoffrey C / Seow, Cynthia H / Maxwell, Cynthia / Huang, Vivian / Leung, Yvette / Jones, Jennifer / Leontiadis, Grigorios I / Tse, Frances / Mahadevan, Uma / van der Woude, C Janneke / Anonymous1790853 / Anonymous1800853. ·Mount Sinai Hospital Centre for Inflammatory Bowel Disease, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: geoff.nguyen@utoronto.ca. · Departments of Medicine & Community Health Sciences, University of Calgary, Calgary, Alberta, Canada. · Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ontario, Canada. · Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. · Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada. · Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. · Department of Medicine, McMaster University, Hamilton, Ontario, Canada. · Department of Medicine, University of California, San Francisco, San Francisco, California. · Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands. · ·Gastroenterology · Pubmed #26688268.

ABSTRACT: BACKGROUND & AIMS: The management of inflammatory bowel disease (IBD) poses a particular challenge during pregnancy because the health of both the mother and the fetus must be considered. METHODS: A systematic literature search identified studies on the management of IBD during pregnancy. The quality of evidence and strength of recommendations were rated using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. RESULTS: Consensus was reached on 29 of the 30 recommendations considered. Preconception counseling and access to specialist care are paramount in optimizing disease management. In general, women on 5-ASA, thiopurine, or anti-tumor necrosis factor (TNF) monotherapy for maintenance should continue therapy throughout pregnancy. Discontinuation of anti-TNF therapy or switching from combination therapy to monotherapy may be considered in very select low-risk patients. Women who have a mild to moderate disease flare while on optimized 5-ASA or thiopurine therapy should be managed with systemic corticosteroid or anti-TNF therapy, and those with a corticosteroid-resistant flare should start anti-TNF therapy. Endoscopy or urgent surgery should not be delayed during pregnancy if indicated. Decisions regarding cesarean delivery should be based on obstetric considerations and not the diagnosis of IBD alone, with the exception of women with active perianal Crohn's disease. With the exception of methotrexate, the use of medications for IBD should not influence the decision to breast-feed and vice versa. Live vaccinations are not recommended within the first 6 months of life in the offspring of women who were on anti-TNF therapy during pregnancy. CONCLUSIONS: Optimal management of IBD before and during pregnancy is essential to achieving favorable maternal and neonatal outcomes.

5 Guideline New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis. 2015

Eliadou, Elena / Day, Andrew S / Thompson-Fawcett, Mark W / Gearry, Richard B / Rowbotham, David S / Walmsley, Russel / Schultz, Michael / Inns, Stephen J / Anonymous8050851 / Anonymous8060851. · · Hutt Valley DHB IBD Service, Private Bag 31907, Lower Hutt 5040 and Department of Medicine, University of Otago, Wellington, on behalf of IBDNZ. stephen.inns@otago.ac.nz. ·N Z Med J · Pubmed #26645757.

ABSTRACT: The management of patients with ulcerative colitis who are dependent on corticosteroid for control of symptoms, or refractory to corticosteroids or standard immunosuppressive therapy, is challenging. The development of newer medical therapies has increased the options for managing patients in this situation, but access and funding remain limited. This guideline summarises the literature regarding this situation and provides guidance as to the management of refractory colitis in the New Zealand setting.

6 Guideline [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]. 2015

Dignass, A / Lindsay, J O / Sturm, A / Windsor, A / Colombel, J-F / Allez, M / d'Haens, G / d'Hoore, A / Mantzanaris, G / Novacek, G / Öresland, T / Reinisch, W / Sans, M / Stange, E / Vermeire, S / Travis, S / van Assche, G. ·Contribuyeron por igual a este trabajo; Coordinadores del Consenso. Electronic address: axel.dignass@fdk.info. · Contribuyeron por igual a este trabajo. · Contribuyeron por igual a este trabajo; Coordinadores del Consenso. · Coordinadores del Consenso. Electronic address: gvanassche@mtsinai.on.ca. ·Rev Gastroenterol Mex · Pubmed #25769217.

ABSTRACT: -- No abstract --

7 Guideline [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations (Spanish version)]. 2015

van Assche, G / Dignass, A / Bokemeyer, B / Danese, S / Gionchetti, P / Moser, G / Beaugerie, L / Gomollón, F / Häuser, W / Herrlinger, K / Oldenburg, B / Panes, J / Portela, F / Rogler, G / Stein, J / Tilg, H / Travis, S / Lindsay, J O. ·En nombre de la ECCO; G.V.A. y A.D. actúan como coordinadores del consenso y han contribuido igualmente para este trabajo. Electronic address: gvanassche@mtsinai.on.ca. · G.V.A. y A.D. actúan como coordinadores del consenso y han contribuido igualmente para este trabajo. Electronic address: axel.dignass@fdk.info. · En nombre de la ECCO. ·Rev Gastroenterol Mex · Pubmed #25769216.

ABSTRACT: -- No abstract --

8 Guideline Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. 2015

Bressler, Brian / Marshall, John K / Bernstein, Charles N / Bitton, Alain / Jones, Jennifer / Leontiadis, Grigorios I / Panaccione, Remo / Steinhart, A Hillary / Tse, Francis / Feagan, Brian / Anonymous2800823. ·Division of Gastroenterology, Department of Medicine, St Paul's Hospital, Vancouver, British Columbia. Electronic address: brian_bressler@hotmail.com. · Department of Medicine, McMaster University, Hamilton, Ontario. · IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba. · Department of Medicine, McGill University Health Centre, Montreal, Quebec. · Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan. · Department of Medicine, University of Calgary, Calgary, Alberta. · Department of Medicine, University of Toronto, Toronto, Ontario. · Robarts Research Institute, Western University, London, Ontario, Canada. · ·Gastroenterology · Pubmed #25747596.

ABSTRACT: BACKGROUND & AIMS: The medical management of ulcerative colitis (UC) has improved through the development of new therapies and novel approaches that optimize existing drugs. Previous Canadian consensus guidelines addressed the management of severe UC in the hospitalized patient. We now present consensus guidelines for the treatment of ambulatory patients with mild to severe active UC. METHODS: A systematic literature search identified studies on the management of UC. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a working group of specialists. RESULTS: The participants concluded that the goal of therapy is complete remission, defined as both symptomatic and endoscopic remission without corticosteroid therapy. The consensus includes 34 statements focused on 5 main drug classes: 5-aminosalicylate (5-ASA), corticosteroids, immunosuppressants, anti-tumor necrosis factor (TNF) therapies, and other therapies. Oral and rectal 5-ASA are recommended first-line therapy for mild to moderate UC, with corticosteroid therapy for those who fail to achieve remission. Patients with moderate to severe UC should undergo a course of oral corticosteroid therapy, with transition to 5-ASA, thiopurine, anti-TNF (with or without thiopurine or methotrexate), or vedolizumab maintenance therapy in those who successfully achieve symptomatic remission. For patients with corticosteroid-resistant/dependent UC, anti-TNF or vedolizumab therapy is recommended. Timely assessments of response and remission are critical to ensuring optimal outcomes. CONCLUSIONS: Optimal management of UC requires careful patient assessment, evidence-based use of existing therapies, and thorough assessment to define treatment success.

9 Guideline Colonoscopy surveillance for dysplasia and colorectal cancer in patients with inflammatory bowel disease. 2015

Aalykke, Claus / Jensen, Michael Dam / Fallingborg, Jan / Jess, Tine / Langholz, Ebbe / Meisner, Søren / Andersen, Nynne Nyboe / Riis, Lene Buhl / Thomsen, Ole Østergaard / Tøttrup, Anders. ·Department of Medicine, OUH, Svendborg Sygehus, 5700 Svendborg, Denmark. claus.aalykke@rsyd.dk. · ·Dan Med J · Pubmed #25557336.

ABSTRACT: The risk of colorectal cancer (CRC) and dysplasia in patients with inflammatory bowel disease (IBD) has been highly debated as risk estimates from different studies vary greatly. The present national Danish guideline on colonoscopy surveillance for dysplasia and colorectal cancer in patients with IBD is based on a thorough review of existing literature with particular focus on recent studies from Denmark revealing a lower risk of CRC than previously assumed. The overall risk of CRC in the Danish IBD population does not appear to be different from that of the background population; however, in some subgroups of patients the risk is increased. These subgroups of patients, who should be offered colonoscopy surveillance, include patients with ulcerative colitis having extensive disease and a long disease duration (10-13 years); early age at onset (less than 19 years of age) of ulcerative colitis; and patients with ulcerative colitis as well as Crohn's disease with a concomitant diagnosis of primary sclerosing cholangitis. A colonoscopy surveillance program is recommended in these subgroups with intervals ranging from every 3-6 months to every 5 years, using chromoendoscopy with targeted biopsies of the lesion and adjacent mucosa, instead of conventional colonoscopy with random biopsies. Preferably, the colonoscopy should be performed during clinical remission. If a lesion is detected the endoscopical resectability together with the pathology of the lesion and the adjacent mucosa determine how the lesion should be treated.

10 Guideline [Reccomendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease]. 2015

Gomollón, Fernando / Rubio, Saioa / Charro, Mara / García-López, Santiago / Muñoz, Fernando / Gisbert, Javier P / Domènech, Eugeni / Anonymous1330940. ·Servicio de Aparato Digestivo, Hospital Clínico Universitario Lozano Blesa, Zaragoza, IIS Aragón, España Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD). Electronic address: fgomollon@gmail.com. · Servicio de Aparato Digestivo, Hospital de Navarra, PamplonaEspaña. · Servicio de Aparato Digestivo, Hospital Royo Villanova, Zaragoza España. · Servicio de Aparato Digestivo, Hospital Universitario Miguel Servet, Zaragoza, España. · Servicio de Aparato Digestivo, Hospital de León, León España. · Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid España, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD). · Servicio de Aparato Digestivo, Hospital Germans Trías i Pujol, Badalona España, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD). · ·Gastroenterol Hepatol · Pubmed #25454602.

ABSTRACT: Methotrexate is an immunosuppressant that may be useful in several clinical scenarios in inflammatory bowel disease. In this article, we review the available evidence in Crohn's disease and ulcerative colitis and establish general recommendations for its use in clinical practice. Although the available data are limited, it is very likely that methotrexate is underused because its effectiveness is underestimated and its toxicity is overestimated. Both in induction therapy and in maintenance of remission, methotrexate is useful in Crohn's disease. When prescribed in combination with biologic agents, immunogenicity is less frequent and consequently long-term response could potentially be improved. There are few published studies, but several data suggest that methotrexate could also be useful in ulcerative colitis. Although myelotoxicity and liver toxicity are well known risks, methotrexate is a drug that is well tolerated in many patients, even in the long term.

11 Guideline Practice parameters for the surgical treatment of ulcerative colitis. 2014

Ross, Howard / Steele, Scott R / Varma, Mika / Dykes, Sharon / Cima, Robert / Buie, W Donald / Rafferty, Janice / Anonymous3070778. ·Prepared by the Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. · ·Dis Colon Rectum · Pubmed #24316941.

ABSTRACT: -- No abstract --

12 Guideline ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. 2014

Levine, Arie / Koletzko, Sibylle / Turner, Dan / Escher, Johanna C / Cucchiara, Salvatore / de Ridder, Lissy / Kolho, Kaija-Leena / Veres, Gabor / Russell, Richard K / Paerregaard, Anders / Buderus, Stephan / Greer, Mary-Louise C / Dias, Jorge A / Veereman-Wauters, Gigi / Lionetti, Paolo / Sladek, Malgorzata / Martin de Carpi, Javier / Staiano, Annamaria / Ruemmele, Frank M / Wilson, David C / Anonymous15781309. ·*Pediatric Gastroenterology and Nutrition Unit, Wolfson Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel †Dr von Hauner Children's Hospital, Ludwig Maximilians University, Munich, Germany ‡Pediatric Gastroenterology Unit, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Israel §Pediatric Gastroenterology, Department of Pediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands ||Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Italy ¶Children's Hospital, University of Helsinki, Helsinki, Finland #Semmelweis University, Budapest, Hungary **Department of Paediatric Gastroenterology and Nutrition, Yorkhill Children's Hospital, Glasgow, UK ††Department of Paediatrics, Hvidovre University Hospital, Copenhagen, Denmark ‡‡St.-Marien-Hospital, Department of Pediatrics, Bonn, Germany §§Department of Diagnostic Imaging, The Hospital for Sick Children ||||Department of Medical Imaging, University of Toronto, Toronto Canada ¶¶Hospital S. João, Porto, Portugal ##Pediatric Gastroenterology and Nutrition, UZ Brussels, Brussels, Belgium ***Departement Neurofarba, University of Florence, Meyer Children Hospital, Florence, Italy †††Department of Pediatrics, Gastroenterology and Nutrition, Jagiellonian University Medical College, Cracow, Poland ‡‡‡Department of Pediatric Gastroenterology, Hepatology and Nutrition, Hospital Sant Joan de Déu, Barcelona, Spain §§§Department of Translational Medical Sciences, Section of Pediatrics, University of Naples "Federico II," Naples, Italy ||||||Université Sorbonne Paris Cité, Université Paris Descartes, INSERM U989, AP-HP, Hôpital Necker Enfants Malades, Service de Gastroentérologie Pédiatrique, Paris, France ¶¶¶Child Life and Health, University of Edinburgh, Edinburgh, UK. · ·J Pediatr Gastroenterol Nutr · Pubmed #24231644.

ABSTRACT: BACKGROUND: The diagnosis of pediatric-onset inflammatory bowel disease (PIBD) can be challenging in choosing the most informative diagnostic tests and correctly classifying PIBD into its different subtypes. Recent advances in our understanding of the natural history and phenotype of PIBD, increasing availability of serological and fecal biomarkers, and the emergence of novel endoscopic and imaging technologies taken together have made the previous Porto criteria for the diagnosis of PIBD obsolete. METHODS: We aimed to revise the original Porto criteria using an evidence-based approach and consensus process to yield specific practice recommendations for the diagnosis of PIBD. These revised criteria are based on the Paris classification of PIBD and the original Porto criteria while incorporating novel data, such as for serum and fecal biomarkers. A consensus of at least 80% of participants was achieved for all recommendations and the summary algorithm. RESULTS: The revised criteria depart from existing criteria by defining 2 categories of ulcerative colitis (UC, typical and atypical); atypical phenotypes of UC should be treated as UC. A novel approach based on multiple criteria for diagnosing IBD-unclassified (IBD-U) is proposed. Specifically, these revised criteria recommend upper gastrointestinal endoscopy and ileocolonscopy for all suspected patients with PIBD, with small bowel imaging (unless typical UC after endoscopy and histology) by magnetic resonance enterography or wireless capsule endoscopy. CONCLUSIONS: These revised Porto criteria for the diagnosis of PIBD have been developed to meet present challenges and developments in PIBD and provide up-to-date guidelines for the definition and diagnosis of the IBD spectrum.

13 Guideline [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. 2013

Gomollón, Fernando / García-López, Santiago / Sicilia, Beatriz / Gisbert, Javier P / Hinojosa, Joaquín / Anonymous2430775. · ·Gastroenterol Hepatol · Pubmed #24215088.

ABSTRACT: -- No abstract --

14 Guideline Endoscopy in inflammatory bowel disease: recommendations from the IBD Committee of the French Society of Digestive Endoscopy (SFED). 2013

Peyrin-Biroulet, Laurent / Bonnaud, Guillaume / Bourreille, Arnaud / Chevaux, Jean-Baptiste / Faure, Patrick / Filippi, Jérôme / Laharie, David / Vuitton, Lucine / Bulois, Philippe / Gonzalez, Florent / Trang, Caroline / Koch, Stéphane / Bernardini, David / Cellier, Christophe / Anonymous5740773. ·Inserm U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy-Brabois, Université Henri Poincaré 1, 54511 Vandoeuvre-lès-Nancy. · ·Endoscopy · Pubmed #24165822.

ABSTRACT: -- No abstract --

15 Guideline European consensus on the histopathology of inflammatory bowel disease. 2013

Magro, F / Langner, C / Driessen, A / Ensari, A / Geboes, K / Mantzaris, G J / Villanacci, V / Becheanu, G / Borralho Nunes, P / Cathomas, G / Fries, W / Jouret-Mourin, A / Mescoli, C / de Petris, G / Rubio, C A / Shepherd, N A / Vieth, M / Eliakim, R / Anonymous4850764 / Anonymous4860764. ·Department of Pharmacology & Therapeutics, Institute for Molecular and Cell Biology, Faculty of Medicine University of Porto, Department of Gastroenterology, Hospital de Sao Joao, Porto, Portugal. Electronic address: fm@med.up.pt. · ·J Crohns Colitis · Pubmed #23870728.

ABSTRACT: The histologic examination of endoscopic biopsies or resection specimens remains a key step in the work-up of affected inflammatory bowel disease (IBD) patients and can be used for diagnosis and differential diagnosis, particularly in the differentiation of UC from CD and other non-IBD related colitides. The introduction of new treatment strategies in inflammatory bowel disease (IBD) interfering with the patients' immune system may result in mucosal healing, making the pathologists aware of the impact of treatment upon diagnostic features. The European Crohn's and Colitis Organisation (ECCO) and the European Society of Pathology (ESP) jointly elaborated a consensus to establish standards for histopathology diagnosis in IBD. The consensus endeavors to address: (i) procedures required for a proper diagnosis, (ii) features which can be used for the analysis of endoscopic biopsies, (iii) features which can be used for the analysis of surgical samples, (iv) criteria for diagnosis and differential diagnosis, and (v) special situations including those inherent to therapy. Questions that were addressed include: how many features should be present for a firm diagnosis? What is the role of histology in patient management, including search for dysplasia? Which features if any, can be used for assessment of disease activity? The statements and general recommendations of this consensus are based on the highest level of evidence available, but significant gaps remain in certain areas.

16 Guideline [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. 2013

Cabriada, José Luis / Vera, Isabel / Domènech, Eugeni / Barreiro-de Acosta, Manuel / Esteve, María / Gisbert, Javier P / Panés, Julia / Gomollón, Fernando / Anonymous1130751. ·Servicio de Aparato Digestivo, Hospital Galdakao-Usansolo, Galdakao, Vizcaya, España. jcabriada@gmail.com · ·Gastroenterol Hepatol · Pubmed #23433780.

ABSTRACT: -- No abstract --

17 Guideline Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU. 2013

Gomollón, Fernando / García-López, Santiago / Sicilia, Beatriz / Gisbert, Javier P / Hinojosa, Joaquín / Anonymous50748. ·Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, Instituto de Investigación Sanitaria, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Zaragoza, Spain. fgomollon@gmail.com · ·Gastroenterol Hepatol · Pubmed #23332546.

ABSTRACT: BACKGROUND AND AIM: Evidence-based clinical guidelines on Ulcerative colitis (UC) have been developed through a consensus, while GRADE methodology is the current standard for guideline development. This is the first one based on GRADE methodology on UC. METHODS: Following GRADE methodology, the Spanish Group of Ulcerative Colitis and Crohn's disease (GETECCU) have developed a guideline on UC treatment. After selection of relevant clinical scenarios, 32 clinical questions were chosen and recommendations were established. RESULTS: In 2 questions no recommendation was possible. Twenty-two actions were recommended for, 14 strongly and 8 weakly. However, in 8 questions a recommendation against doing something was obtained, weak in 5 and strong in 3. The majority of recommendations were based on moderate quality evidence, and only 5 on high-quality evidence. CONCLUSIONS: With GRADE methodology we find a clear recommendation on possible actions in most clinical decisions in UC treatment, but much more clinical high-quality research is needed.

18 Guideline Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. 2013

Van Assche, Gert / Dignass, Axel / Bokemeyer, Bernd / Danese, Silvio / Gionchetti, Paolo / Moser, Gabriele / Beaugerie, Laurent / Gomollón, Fernando / Häuser, Winfried / Herrlinger, Klaus / Oldenburg, Bas / Panes, Julian / Portela, Francisco / Rogler, Gerhard / Stein, Jürgen / Tilg, Herbert / Travis, Simon / Lindsay, James O / Anonymous130739. ·Division of Gastroenterology, Department of Medicine, Mt. Sinai Hospital and University Health Network,University of Toronto and University of Leuven, 600 University Avenue, Toronto, ON, Canada M5G 1X5. gvanassche@mtsinai.on.ca · ·J Crohns Colitis · Pubmed #23040453.

ABSTRACT: -- No abstract --

19 Guideline Indian Society of Gastroenterology consensus on ulcerative colitis. 2012

Ramakrishna, Balakrishnan S / Makharia, Govind K / Abraham, Philip / Ghoshal, Uday C / Jayanthi, Venkataraman / Agarwal, Brij Kishore / Ahuja, Vineet / Bhasin, Deepak K / Bhatia, Shobna J / Choudhuri, Gourdas / Dadhich, Sunil / Desai, Devendra C / Dhali, Gopal Krishna / Goswami, Bhaba Dev / Issar, Sanjeev K / Jain, Ajay K / Kochhar, Rakesh / Kumar, Ajay / Loganathan, Goundappa / Misra, Sri Prakash / Pai, C Ganesh / Pal, Sujoy / Pulimood, Anna / Puri, Amarender S / Ramesh, Ganesh N / Ray, Gautam / Singh, Shivaram P / Sood, Ajit / Tandan, Manu / Anonymous1661380. ·Department of Gastrointestinal Sciences, Christian Medical College, Vellore 632 004, India. rama@cmcvellore.ac.in · ·Indian J Gastroenterol · Pubmed #23096266.

ABSTRACT: In 2010, the Indian Society of Gastroenterology's Task Force on Inflammatory Bowel Diseases undertook an exercise to produce consensus statements on ulcerative colitis. This consensus, produced through a modified Delphi process, reflects our current understanding of the definition, diagnostic work up, treatment and complications of ulcerative colitis. The consensus statements are intended to serve as a reference point for teaching, clinical practice, and research in India.

20 Guideline Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. 2012

Turner, Dan / Levine, Arie / Escher, Johanna C / Griffiths, Anne M / Russell, Richard K / Dignass, Axel / Dias, Jorge Amil / Bronsky, Jiri / Braegger, Christian P / Cucchiara, Salvatore / de Ridder, Lissy / Fagerberg, Ulrika L / Hussey, Séamus / Hugot, Jean-Pierre / Kolacek, Sanja / Kolho, Kaija Leena / Lionetti, Paolo / Paerregaard, Anders / Potapov, Alexander / Rintala, Risto / Serban, Daniela E / Staiano, Annamaria / Sweeny, Brian / Veerman, Gigi / Veres, Gabor / Wilson, David C / Ruemmele, Frank M / Anonymous1551380 / Anonymous1561380. ·Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Israel. turnerjd2001@gmail.com · ·J Pediatr Gastroenterol Nutr · Pubmed #22773060.

ABSTRACT: BACKGROUND AND AIMS: Pediatric ulcerative colitis (UC) shares many features with adult-onset disease but there are some unique considerations; therefore, therapeutic approaches have to be adapted to these particular needs. We aimed to formulate guidelines for managing UC in children based on a systematic review (SR) of the literature and a robust consensus process. The present article is a product of a joint effort of the European Crohn's and Colitis Organization (ECCO) and the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). METHODS: A group of 27 experts in pediatric IBD participated in an iterative consensus process including 2 face-to-face meetings, following an open call to ESPGHAN and ECCO members. A list of 23 predefined questions were addressed by working subgroups based on a SR of the literature. RESULTS: A total of 40 formal recommendations and 68 practice points were endorsed with a consensus rate of at least 89% regarding initial evaluation, how to monitor disease activity, the role of endoscopic evaluation, medical and surgical therapy, timing and choice of each medication, the role of combined therapy, and when to stop medications. A management flowchart, based on the Pediatric Ulcerative Colitis Activity Index (PUCAI), is presented. CONCLUSIONS: These guidelines provide clinically useful points to guide the management of UC in children. Taken together, the recommendations offer a standardized protocol that allows effective, timely management and monitoring of the disease course, while acknowledging that each patient is unique.

21 Guideline [Guidelines for the management of ulcerative colitis]. 2012

Choi, Chang Hwan / Kim, Young-Ho / Kim, You Sun / Ye, Byong Duk / Lee, Kang Moon / Lee, Bo In / Jung, Sung-Ae / Kim, Won Ho / Lee, Heeyoung / Anonymous421078. ·Department of Internal Medicine, Chung-Ang University College of Medicine, Korea. · ·Korean J Gastroenterol · Pubmed #22387836.

ABSTRACT: Ulcerative colitis (UC) is a chronic inflammatory bowel disorder characterized by a relapsing and remitting course. The quality of life can decreases significantly during exacerbations of the disease. The incidence and prevalence of UC in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Various medical and surgical therapies are currently used for the management of UC. However, many challenging issues exist and sometimes these lead to differences in practice between clinicians. Therefore, Inflammatory Bowel Diseases (IBD) Study Group of Korean Association for the Study of Intestinal Diseases (KASID) set out the Korean guidelines for the management of UC. These guidelines are made by the adaptation using several foreign guidelines and encompass treatment of active colitis, maintenance of remission and indication for surgery in UC. The specific recommendations are presented with the quality of evidence. These are the first Korean treatment guidelines for UC and will be revised with new evidences on treatment of UC.

22 Guideline Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. 2012

Bitton, Alain / Buie, Donald / Enns, Robert / Feagan, Brian G / Jones, Jennifer L / Marshall, John K / Whittaker, Scott / Griffiths, Anne M / Panaccione, Remo / Anonymous2530711. ·McGill University Health Centre, Montreal, Quebec, Canada. alain.bitton@muhc.mcgill.ca · ·Am J Gastroenterol · Pubmed #22108451.

ABSTRACT: OBJECTIVES: The objective of this study was to provide updated explicit and relevant consensus statements for clinicians to refer to when managing hospitalized adult patients with acute severe ulcerative colitis (UC). METHODS: The Canadian Association of Gastroenterology consensus group of 23 voting participants developed a series of recommendation statements that addressed pertinent clinical questions. An iterative voting and feedback process was used to do this in conjunction with systematic literature reviews. These statements were brought to a formal consensus meeting held in Toronto, Ontario (March 2010), when each statement was discussed, reformulated, voted upon, and subsequently revised until group consensus (at least 80% agreement) was obtained. The modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) criteria were used to rate the strength of recommendations and the quality of evidence. RESULTS: As a result of the iterative process, consensus was reached on 21 statements addressing four themes (General considerations and nutritional issues, Steroid use and predictors of steroid failure, Cyclosporine and infliximab, and Surgical issues). CONCLUSIONS: Key recommendations for the treatment of hospitalized patients with severe UC include early escalation to second-line medical therapy with either infliximab or cyclosporine in individuals in whom parenteral steroids have failed after 72 h. These agents should be used in experienced centers where appropriate support is available. Sequential therapy with cyclosporine and infliximab is not recommended. Surgery is an option when first-line steroid therapy fails, and is indicated when second-line medical therapy fails and/or when complications arise during the hospitalization.

23 Guideline [Surveillance of patients with inflammatory bowel diseases]. 2011

Moshkowitz, Menachem / Kariv, Revital / Half, Betsei / Vilkin, Alex / Levi, Zohar / Niv, Yaron / Dotan, Iris / Anonymous640713. ·The Section of Gastrointestinal Oncology, the Israeli Gastroenterology Association. · ·Harefuah · Pubmed #22164923.

ABSTRACT: This position paper of the Section of Gastrointestinal Oncology of the Israeli Gastroenterological Association recommends specific guidelines for colorectal cancer surveillance in patients with inflammatory bowel disease. Colorectal cancer (CRC) is a severe complication of inflammatory bowel disease (IBD), generally developing into a longstanding disease. The Lifetime prevalence of CRC in ulcerative colitis (UC) patients is estimated to be 2% after 10 years, 8% after 20 years, and even 18% after 30 years of extensive disease. Screening colonoscopy should be initiated 8-10 years after onset of symptoms in extensive UC patients (pancolitis), and after 15 years in patients with left-sided colitis (UC or Crohn's). Surveillance should continue periodically at an interval of every 1 to 2 years. Surveillance colonoscopies should be performed in combination with an extensive biopsy protocol. High-grade dysplasia (HGD) in flat mucosa or a dysplasia associated Lesion or mass (DALM) is considered an indication for colectomy when the pathological findings are confirmed by a second experienced pathologist. Further research is directed toward improving detection of dysplasia during colonoscopy through the use of novel endoscopic imaging techniques which are hoped to impact the approach to cancer prevention in patients with IBD.

24 Guideline [Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011]. 2011

Dignass, A / Preiss, J C / Aust, D E / Autschbach, F / Ballauff, A / Barretton, G / Bokemeyer, B / Fichtner-Feigl, S / Hagel, S / Herrlinger, K R / Jantschek, G / Kroesen, A / Kruis, W / Kucharzik, T / Langhorst, J / Reinshagen, M / Rogler, G / Schleiermacher, D / Schmidt, C / Schreiber, S / Schulze, H / Stange, E / Zeitz, M / Hoffmann, J C / Stallmach, A. ·Medizinische Klinik I, Gastroent., Hepatologie, Onkologie und Infektiologie, Agaplesion Markus Krankenhaus, Frankfurt/Main. axel.dignass@fdk.info · ·Z Gastroenterol · Pubmed #21866493.

ABSTRACT: -- No abstract --

25 Guideline Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. 2011

Turner, Dan / Travis, Simon P L / Griffiths, Anne M / Ruemmele, Frank M / Levine, Arie / Benchimol, Eric I / Dubinsky, Marla / Alex, George / Baldassano, Robert N / Langer, Jacob C / Shamberger, Robert / Hyams, Jeffrey S / Cucchiara, Salvatore / Bousvaros, Athos / Escher, Johanna C / Markowitz, James / Wilson, David C / van Assche, Gert / Russell, Richard K / Anonymous3431308 / Anonymous3441308. ·Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel. turnerd@szmc.org.il · ·Am J Gastroenterol · Pubmed #21224839.

ABSTRACT: OBJECTIVES: Acute severe ulcerative colitis (ASC) is a potentially life-threatening disease. We aimed to formulate guidelines for managing ASC in children based on systematic review of the literature and robust consensus process. This manuscript is a product of a joint effort of the ECCO (European Crohn's and Colitis Organization), the Pediatric Porto Inflammatory Bowel Disease (IBD) Working group of ESPGHAN (European Society of Pediatric Gastroenterology, Hepatology, and Nutrition) and ESPGHAN. METHODS: A group of 19 experts in pediatric IBD participated in an iterative consensus process including two face-to-face meetings. A total of 17 predefined questions were addressed by working subgroups based on a systematic review of the literature. RESULTS: The recommendations and practice points were eventually endorsed with a consensus rate of at least 95% regarding: definitions, initial evaluation, standard therapy, timing of second-line therapy, the role of endoscopic evaluation and heparin prophylaxis, how to administer second-line medical therapy, how to assess response, surgical considerations, and discharge recommendations. A management flowchart is presented based on daily scoring of the Pediatric Ulcerative Colitis Activity Index (PUCAI), along with 28 formal recommendations and 34 practice points. CONCLUSIONS: These guidelines provide clinically useful points to guide the management of ASC in children. Taken together, the recommendations offer a standardized protocol that allows effective monitoring of disease progress and timely treatment escalation when needed.

Next